Beech Tree Labs offers an attractive profile for investors and partners. Highlights include:
Novel Technology
- Typically comprised of naturally-occurring molecules;
- Physiologic dosage;
- Large portfolio of domestic and foreign patents and patent applications.
Emerging Platform
- Many unrelated diseases treated with different formulations by various investigators;
- Elan Corporation, plc, licensed more than 30 patents to move forward their Alzheimer’s research now in FDA Phase 2 trials;
- 2 open IND applications on file;
- Several publications in peer-reviewed journals;
- Decades of pre-clinical and clinical studies;
- Consistently positive results with placebo-level adverse effects.
The Company
- An established base of patented product candidates, several ready for formal clinical evaluation;
- A low burn rate and a proven cost and time effective product development strategy;
- Products with inherently low risk of side effects and high profit margin potential;
- No capital-intensive manufacturing process;
- Robust pipeline.
Management Team Successes
- 13 FDA-authorized clinical trials;
- 2 IRB-approved clinical trials;
- 1 USDA-approved clinical trial;
- World’s first live-virus fish vaccine;
- Alzheimer’s disease pioneer;
- Nutraceutical product, Mucolyxir® on the market;
- Built extensive network of physicians, veterinarians, and medical scientists.
Security
- All patents owned, or licensed to, the company.
Markets
- Pharmaceutical;
- Nutraceutical;
- Product candidates may also be developed in parallel for the above markets.